The autoantigen p90 is a recently discovered protein that binds to and inhibits Protein Phosphatase 2A (PP2A) activity, thereby playing a critical role in cancer progression. Thus, p90 was renamed the "cancerous inhibitory protein of PP2A" or CIP2A. Most interestingly CIP2A was shown to inhibit of the degradation of c-Myc oncoprotein and was reported to be overexpressed in several cancers (1). However, the clinical relevance of CIP2A to human cancers had not been demonstrated, and the mechanism of its regulation and its clinical role in cancer are unknown. A recent study evaluated tissue microarrays consisting of 223 gastric adenocarcinoma using CIP2A antibodies in immunohistochemistry. CIP2A expression was found to be a predictor of survival for some subgroups of gastric cancer patients and thus CIP2A and MYC appear to be regulated in a positive feedback loop, wherein they promote each other's expression and gastric cancer cell proliferation (2). The functional role of CIP2A in breast cancer cells was evaluated by small interfering RNA-mediated depletion of the protein followed by an analysis of cell proliferation, migration, anchorage-independent growth, and xenograft growth by monitoring the protein levels of CIP2A using antibodies. Findings from the study revealed that CIP2A is associated with clinical aggressiveness in human breast cancers. Available evidence warrants further investigation of CIP2A as a therapeutic target in cancers and is an open area of research. Novus Biologicals offers an array of research tools for your CIP2A research needs in the form of antibodies, siRNA and cell lysates.
Novus Biologicals offers CIP2A reagents for your research needs including:
